The BioValley business model: From a high potential in basic research to the creation of new companies
|
|
- Bernard Poole
- 7 years ago
- Views:
Transcription
1 The BioValley business model: From a high potential in basic research to the creation of new companies OECD Workshop on basic research October 2001, Oslo, Norway Sylvie Schott-Reverberi
2 INTRODUCTION BIOTECHNOLOGY : WHERE SCIENCE MEETS BUSINESS
3 Definition: «Biotechnology is the use of living organisms with high technology tools, supported by highly innovative research, with the aim of producing / commercializing either products and or services». The Bio-industry: indissociable from intellectual & scientific excellence. The life science sector is among the outstanding industrial sectors of the new millennium.
4 OVERVIEW OF THE BIOTECHNOLOGY INDUSTRY IN EUROPE Evolution of the biotech sector in Europe Number of biotech companies per country Number of biotech companies in Europe & in the US
5 Number of Biotech Companies per Country Million Euros Number Employees Revenue of companies (in million of Euros) United Kingdom Germany France Switzerland Reste Europe Total Source : Ernst&Young "Life Sciences in France
6 WHY ARE BIOTECHNOLOGIES CONSIDERED AS A NEW BUSINESS MODEL? (1) The American leadership : strong interconnection between networks of companies (big pharmas and biotech start-ups), financers from risk-capital and public research institutions : Í Easy access to risk-capital Í Facilities for technology transfer
7 WHY ARE BIOTECHNOLOGIES CONSIDERED AS A NEW BUSINESS MODEL? (2) The European mindshift : Í New entrepreneurial mindshift in the scientific community ; Í New facilities for the creation of start-ups (European and Governmental measures) Í Outsourcing of R&D programmes of the big pharmas (4% in % in 2000)
8 Events in Europe in 2000 l l l l l +16% of new biotech companies in Europe. The number of biotech companies in now higher in Europe than in the US. But the number of their employees are still 2.5 time higher. Very young industrial sector with 50% of the new companies created for less than 4 years. High growth in the numbers of pharmaceutical products under trial : + 40% between 99 and Revenue of the sector in Europe in 2000 : 6 billions Biotechnology is made of high scientific performance and will produce high economic added value in the next decades
9 THE 3 KEY FACTORS OF SUCCESS TO MAKE SCIENCE MEETS BUSINESS l l l Companies which are world leaders in the field of biotechnology. High quality higher education and research establishments. Favourable economic climate and facilities for the creation of start-ups Ï SOCIAL NETWORK
10 PART 1 The BioValley Social Network
11 I.I. The Initiative A tri-national life-sciences network located at the cross-border of France, Germany & Switzerland A network with more than 2,000 people representing over 500 companies, research institutions, technology transfer centers, public institutions for economic development, bankers, venture capital companies, services companies, suppliers,
12 Prerequisites in the BioValley The Upper Rhine Valley : Alsace, South Baden, North- West Switzerland. Over 300 companies in the field of Life Sciences million inhabitants in the Upper Rhine Valley. 4 universities which together total some students.
13 Main objectives of the BioValley Speeding up technology transfer to boost the creation of biotech start-ups Becoming the most attractive European biotech region for new investments Promoting new alliances with international partners
14 History of the BioValley initiative LATE 80 s : George ENDRESS & Hans BRINER imagine the creation of a «Silicon Valley» dedicated to biotechnology in the Upper Rhine Region : Merger of CIBA SANDOZ into NOVARTIS More than 3000 highly qualified unemployed people Implementation of BioValley concept into a concrete initiative set up by the BioValley Promotion Team : BioValley obtains a budget of euros through the INTERREG II PROGRAMME of the European Union : Creation of the legal structures of BioValley : 3 national associations and 1 central tri-national association : Privatisation of the BioValley initiative
15 BioValley The network that provides the users with a package of services BioValley-Easy-Access System BioValley Guide (Yellow pages) Internet site BioValley Extranet and technology watch BioValley Roof for participation in trade-fairs and exhibitions (trinational presentations) BioValley Universities Partnership Programme with Award-Programme BioValley Stammtische Scientific and Partnering Conferences Continuing Education Programmes Meeting points (e.g. with capital providers)
16 PART 2 THE BIOVALLEY KEY FACTORS FOR SUCCESS
17 I- HIGH QUALITY HIGHER EDUCATION & RESEARCH ESTABLISHMENTS (1) The entire chain of activities in Life Sciences from basic molecular research to drug production is prominent in BioValley. BioValley has one of the highest densities of Life Sciences related research in the world, totaling more then scientists. In BioValley, more then scientists with a higher academic degree (MS, PhD) work in Life Sciences research in over 160 academic and/or public institutions and in over 400 research groups.
18 HIGH QUALITY HIGHER EDUCATION & RESEARCH ESTABLISHMENTS (2) More than out of those scientists (60%) in public research in BioValley are active in Basic Research. Focus areas in public Life Sciences research institutions in BioValley are : Chemistry, Physics/Nanosciences, Genomics/Genetics, Neurosciences, Cell & Development Biology, Oncology, Immunology/Hematology, Pharmacology and Infectious Diseases. The quality of the scientific work is best demonstrated by the fact that, in the last 25 years, 5 Noble Prizes for research in Chemistry, Immunology and Genetics have been awarded to scientists working in BioValley. The combined state-of-the-art knowledge in chemistry and biology is a unique competitive advantage of BioValley in Life Sciences research.
19 There are more scientists active in Basic Research in BioValley than in Applied Research. This reflects the main objective of publicly funded research namely to provide fundamental skills and knowledge for a wide variety of potential applications, rather than supporting specific applications-oriented needs.
20 II - HIGH DENSITY OF WORLD LEADING LIFE SCIENCES COMPANIE & START-UPS
21 Main world-wide «Big Pharmas» represented in the BioValley area 8QLTXH(XURSHDQFOLQLFDOUHVHDUFKFHQWUH (XURSHDQUHVHDUFKFHQWUH
22 START-UPS 121 companies created from 1997 until 2000, 41 of them supported by the BioValley expertise fund France : 20 projects Euroclide MY 68 GeneScan France Prestwick Chemicals Sediag Synth E163 Bioclavis Proteogenix Phitools InOmics PolyPlus Transfection Neuro 3D Germany : 15 projects BioTissue Technologies Diarect AG Genovac Greenovation Myocontract Recovax Stürken VivaCell Switzerland : 6 projects OncoScore Screening Cnter DiaGene Swiss Transgene Mimetica Neutris
23 III - FAVORABLE ECONOMIC CONDITIONS lbiotech-parks in Allschwil (CH), Freiburg (D) and Illkirch-Strasbourg (F). lcreation of a BioValley Fund. leasy access to risk-capital companies in the 3 countries. lgovernmental support.
24 PART 3 The BioValley Business Model
25 1. Privatising BioValley Main Goal of the new structure : «wearing it self from governement support and becoming a self sustaining organization while at the same time continuing to promote the growth of life sciences companies and jobs» BioValley Central Association (Interreg III programme) Association Alsace BioValley BioValley Deutschland e.v. BioValley Platform Basel (F) (D) (CH) 51% 51% 51% x % BioValley Company Alsace BioValley Company BioValley Company Basel Deutschland 49% 49% 49% The BioValley Company AG
26 The BioValley Company AG : sustainability of the BioValley initiative. Trinational private holding company. Will coordinate the business activities in the 3 national BioValley companies. Interaction with the BioValley central association and the 3 national BioValley associations.
27 Missions of the BioValley Company AG Communication tools & strategy Organization of conferences and public debates Creation of technological plate-forms E-business services Start-ups coaching (business plan, marketing strategy, legal advices, industrial property) BioValley monographs Human resources management
28 Developing the creation of new companies & new jobs Phase 1 Phase 2 Phase 3a Phase 4 Phase 5 Detection of projects or skills relating to technology and worth promotion Promotion and pre-incubation Platform including funding for pre-start off phase Bio-incubators including starting off funds. Bio-nursery or biotech companies hotels including venture capital funds. Development of real estate projects specific to biotech companies. Actual or virtual common technological platform Phase 3 b Development of private/public Scientific partnership and/or transfers of technologies. Expected achievement : new firms (spin offs of public research institutions & big pharmas) to new jobs within 10 years.
29
The NEXT Biotechnology
Bernhard Fuhrer The NEXT Biotechnology Beyond the Attempts at Cloning Biotech Clusters Hamburg 2005 Table of Contents 1. Introduction 1 2. An explorative look at biotech clusters 9 2.1 Definition of biotechnology
More informationwww.uea.ac.uk/pha WHAT WILL YOU DISCOVER?
www.uea.ac.uk/pha WHAT WILL YOU DISCOVER? PHARMACOLOGY AND DRUG DISCOVERY UNDERGRADUATE COURSES 2016 WELCOME JOIN US ON A UNIQUE COURSE DESIGNED TO PRODUCE THE UK S NEXT LEADERS IN DRUG DISCOVERY. 1 1
More informationHow To Design A Clinical Trial
BioBusiness BioEntrepreneurship Life Sciences Entrepreneurship BioClub BioClub BioBusiness Network at USI Clinical Trials Design and Management for Start-Up Companies LUGANO: 5-6 NOVEMBER 2012 SUPPORTED
More informationCompany Profile. docount GmbH. pubpress. docount GmbH > www.docount.com > info@docount.ch > +41 61 723 95 95 (P) > +41 61 723 95 96 (F)
docount GmbH pubpress docount GmbH Your partner in Performance Management History In the early nineties, the Swiss companies CIBA AG and SANDOZ AG decided to collect data for all their sites worldwide
More informationInitiatives which promote co-operation and networking: some examples from Switzerland
Initiatives which promote co-operation and networking: some examples from Switzerland By Patrick Vock Centre for Science and Technology Studies (CEST) Swiss Science and Technology Council Bern, Switzerland
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Diego Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Diego Metropolitan Statistical Area Overview and History of Biotechnology in San Diego San Diego has a significant concentration of
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationThe Cluster Initiative Zurich Mednet Swiss Biotechnology Virtual and Real Market Platforms
The Cluster Initiative Zurich Mednet Swiss Biotechnology Virtual and Real Market Platforms Domenico P. Alexakis, Zurich MedNet Introduction Biotechnology and life science are striking examples of the key
More informationMaster of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationSantaravalley: Integrating scientific research, high-tech business and academia Prof. Vladas Algirdas Bumelis President of Santara valley Association Vilnius, Lithuania 2013July 18 th Santara Valley Association
More informationBioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover
The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationThe Role of Research Institutions in the Formation of the Biotech Cluster in Massachusetts
The Role of Research Institutions in the Formation of the Biotech Cluster in Massachusetts Lita Nelsen Massachusetts Institute of Technology Cambridge, December 2005 The Massachusetts Biotech Cluster 2005
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationPr. Dominique JOLLY SKEMA BS. Animatrice : Valérie BLANCHOT COURTOIS
Cycle Innovation & Connaissance 17 petit déjeuner Vendredi 14 février 2014 Comment les entreprises occidentales parient sur la création technologique en Chine? Du cost-driven au knowledge-driven Pr. Dominique
More informationLife Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com
Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationEuropean Forum for Good Clinical Practice. 26 November 2008 - Management Centre Europe, Brussels, Belgium. Children s Medicines Working Party
Programme Version 19 November 2008 The EFGCP Children s Medicines Working Party 4 th Annual Conference EU & US Paediatric Legislation: What is Changing in Practice in Paediatric Drug Treatment, Research
More informationPharmaceutical industry: 2020 and beyond. Driving prosperity, growth, and competitiveness in Switzerland
Pharmaceutical industry: 2020 and beyond Driving prosperity, growth, and competitiveness in Switzerland www.interpharma.ch Pharmaceutical industry: 2020 and beyond Driving prosperity, growth, and competitiveness
More informationAnforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
More informationMSc in Toxicology. Master Degree Programme
Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel
More informationBackground Information
Background Information r One About NAT Testing NAT testing has been widely embraced by laboratories throughout the world as a means to identify CT cases because of its high degree of accuracy and reliability
More informationMolecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationMaster of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
More informationCOOPERATION IN EUROPE
UNIVERSITET 1. MARTS 2013 COOPERATION IN EUROPE - IN GERMAN AND NORDIC HIGHER EDUCATION HAMBURG, JUNE 18, 2013 RECTOR LAURITZ B. HOLM-NIELSEN præsen TATION AGENDA 1. Goal: Innovation Union a competitive
More informationS-GE Impulse: Life Science, April 14, 2015, Messe Basel GLOBAL BIOTECH
S-GE Impulse: Life Science, April 14, 2015, Messe Basel GLOBAL BIOTECH OFFICIAL PROGRAM PREMIUM PARTNER Overview Most biotech companies seek an international strategy and orientation, either for their
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationJOHN REID PhD, MBA. (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1
JOHN REID PhD, MBA (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1 PROFILE Senior-level business development and licensing executive with a well-honed ability to translate scientific
More informationshutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success
shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a
More informationInnovation Policy for SMEs in Germany actual trends
Innovation Policy for SMEs in Germany actual trends Alexander Eickelpasch, German Institute for Economic Research (DIW Berlin), Berlin, Germany Korea-Germany National Competitiveness Forum 2012 Seoul,
More informationOutsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation
More informationAchievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness
2015 Healthcare Healthcare Korea's healthcare industry is growing thanks to the advancement of the production infrastructure of pharmaceuticals, medical devices and cosmetics, support for healthcare-related
More informationProfile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,
More informationBiology Majors Information Session. Biology Advising Center NHB 2.606
Biology Majors Information Session Biology Advising Center NHB 2.606 Biology Advising Center Resources See course descriptions for any of the degree options Find degree checklists for any of the options
More informationThe E-Learning Program of The Vocational Training Center of the National and Kapodistrian University uses innovative educational tools, such as:
Context The E-Learning Program of The Vocational Training Center of the National and Kapodistrian University of Athens, in operation since 2001, provides distance education courses that link theoretical
More informationFacts&figures of pharmaceutical industry in Italy. June 2016
Facts&figures of pharmaceutical industry in Italy June 2016 Key figures of pharma sector in Italy (% on total), member of Farmindustria, representing 90% of industrial value of pharmaceutical sector in
More informationFit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing
Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,
More informationFOR NEGLECTED DISEASES
DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape March 2012 DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape
More informationGlobal Privatization Trends in Healthcare and Health Insurance. Hank Kearney Global Health Access, LLC a PHM International company
Global Privatization Trends in Healthcare and Health Insurance Invest 2001 Dubai 3 April, 2001 Hank Kearney Global Health Access, LLC a PHM International company 2001 INVEST 2001 DUBAI HEALTH CARE & INSURANCE
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationWhen treating a disease is bad business: orphan and neglected diseases
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
More informationUpheaval in the CRM Services Market
Markets, J. Kirkby Research Note 24 October 2002 Upheaval in the CRM Services Market The customer relationship management services market is in upheaval: Competitive changes will strongly influence trends.
More informationAccount Management in times of economic crisis
Account Management in times of economic crisis Isabel Jäckle Key Account Manager Vetter Pharma International GmbH DHBW - Ravensburger Industriegespräche October 19, 2010 Agenda Introduction of the speaker
More informationAPR 14 LIFE SCIENCES PRACTICE GROUP
APR 14 LIFE SCIENCES PRACTICE GROUP OUR Life sciences Practice Pestalozzi s Life Sciences practice group consists of members of our Corporate / M&A, IP & TMT, and Litigation & Arbitration practices. Life
More informationNETWORKING EXPERTISE.
NETWORKING EXPERTISE. 1 PORTRAIT FOCUSED ON THE FUTURE Building and growing a company is a daunting challenge. Success depends on a wide range of inter-related factors. But nothing is more important than
More informationUniversity of Medicine and Dentistry of New Jersey (UMDNJ)
University of Medicine and Dentistry of New Jersey (UMDNJ) Dual-Degree Program between the UMDNJ Graduate School of Biomedical Sciences (GSBS) And the UMDNJ School of Public Health (SPH) Leading to the:
More informationUnderstand life - Preserve the environment. Strategy Document, Department of Biology 2015 2020
Understand life - Preserve the environment Strategy Document, Department of Biology 2015 2020 1 2 Photo: Per Harald Olsen/NTNU Understand life - Preserve the environment Strategy Document for the Department
More informationEBiSC the first European bank for induced pluripotent stem cells
Press Release EBiSC the first European bank for induced pluripotent stem cells Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
More informationCurriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education
Curriculum Vitae Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details Private Address: Date, Place of Birth: Marital Status: Nationality: Languages: Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49
More informationThe majority of pharmaceutical companies in
Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to
More informationAPPENDIX C: ACADEMIC MISSION STATEMENT
APPENDICES APPENDIX C: ACADEMIC MISSION STATEMENT The University of California, San Francisco shares the University s mission of achieving excellence in education, research, and public service. As a graduate
More informationSpinning out in the UK personal experiences and perspectives
Professor Neil A. Williams Head of Department of Cellular and Molecular Medicine Founder, Director of Science, KWS BioTest Ltd Founder, Aegis (Hunter-Fleming) Pharmaceuticals Ltd Spinning out in the UK
More informationReport on the public consultation on the New SME Policy
Report on the public consultation on the New SME Policy 1. Introduction In September 2014, the European Commission launched a public consultation to gather feed-back and ideas on how the Small Business
More informationInvesting in the United States
Investing in the United States 13 May 2015 ehealth Week 2015 Global Markets: Tools for Transatlantic Trade Kim Tuminaro Senior Trade Officer U.S. Department of State SelectUSA.gov U.S. Investment and Business
More informationGene Regulation, Epigenetics and Genome Stability. InternatIonal PhD Programme. In mainz, germany. Helsinki Tallinn. Riga. Moscow Vilnius Minsk.
Helsinki Tallinn Riga InternatIonal PhD Programme Moscow Vilnius Minsk Kiew Sofia Istanbul Ankara Gene Regulation, Epigenetics and Genome Stability In mainz, germany ABouT ThE InTErnATIonAl PhD ProgrAMME
More informationLife Sciences & Healthcare
Life Sciences & Healthcare 03 Taylor Wessing is a leading European law firm advising life sciences and healthcare businesses, those who fund them and those who work for them Taylor Wessing has been voted:
More informationBACHELOR OF SCIENCE IN PHARMACEUTICAL SCIENCES
BACHELOR OF SCIENCE IN PHARMACEUTICAL SCIENCES Albany College of Pharmacy and Health Sciences (ACPHS) offers a four year bachelor degree in Pharmaceutical Sciences, based on a liberal arts core curriculum
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationBioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations
More informationProfile of Biomedical Research and Biotechnology Commercialization. Los Angeles-Riverside-Orange County Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Los Angeles-Riverside-Orange County Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Los Angeles Los
More informationSIPBS Portfolio. 2012-13 Entry
SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationProfile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,
More informationVTT Technical Research Centre of Finland 2010
VTT Technical Research Centre of Finland 2010 02/04/2010 2 GDP share of R&D expenditure in Finland % 3 3.43 3.45 3.48 3.45 3.47 3.72 3.92 2.1 1990 1998 2003 2004 2005 2006 2007 2008 2009 Source: Statistics
More informationMichele Genovese DG Research and Innovation Specific International Cooperation Activities
Michele Genovese DG Research and Innovation Specific International Cooperation Activities 1 2 1. Innovation in a changing, challenging world New Priorities 3 Recent changes in the global economic system
More informationIncreasing Innovation in R&D - Seizing early stage external growth opportunities
Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive
More informationAn Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
More informationPCI Biotech Holding ASA - Second Quarter Report 2008
PCI Biotech Holding ASA - Second Quarter Report 2008 Highlights Demerger and Initial Public Offering at Oslo Axess in June Raised NOK 60 million Per Walday, PhD hired as new CEO Board has been strengthened
More informationEXPO MILANO 2015. Paolo Alli Deputy Commissioner General
EXPO MILANO 2015 Paolo Alli Deputy Commissioner General What s a World Expo? An event involving Governments of the countries around the world, International Organizations, Civil Society and private sector
More informationPh.D Programs at Near East University Faculty of Pharmacy
Ph.D Programs at Near East University Faculty of Pharmacy Ph.D Programs at Near East University, Faculty of Pharmacy NEU Faculty of Pharmacy offers advanced training and education leading toward Ph.D degree.
More informationWe will start momentarily at 2pm ET. Download slides: http://acswebinars.org/borchardt. Contact ACS Webinars at acswebinars@acs.
ACS Webinars We will start momentarily at 2pm ET Download slides: http://acswebinars.org/borchardt Contact ACS Webinars at acswebinars@acs.org 1 Have Questions? Use the Questions Box! Or tweet us using
More informationDegrees in Science (& Physics)
Degrees in Science (& Physics) NUI, Galway College of Science National University of Ireland, Galway Revised January 2008 3 The world has changed...it has become FLAT! Geography no longer matters. Three
More informationEffective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations
Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different
More informationThe Texas Biotechnology Industry
The Texas Biotechnology Industry 2014 Fortune 1000 company NBTY opens state-of-the-art vitamin manufacturing plant in San Antonio See Page 15 Allergan installs new production line at Waco pharmaceutical
More informationBIOTECHNOLOGY. Bouvé College of Health Sciences College of Science. Networked for Success. Networked for Industry. Networked for Life.
MASTER OF SCIENCE BIOTECHNOLOGY Networked for Success. Networked for Industry. Networked for Life. Bouvé College of Health Sciences College of Science Northeastern s Biotechnology Masters program synthesizes
More informationUCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA
UCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA Dr. Henry Daniell Pegasus Professor & University Board of Trustee Chair Dept. Mol.
More informationEnd of Year Event. Perspectives on Executive & Leadership Development. Speaker Profiles
Speaker Profiles Dr Michael Elwell Global Research Director, Core Research, Advanced Materials Division, Huntsman Advanced Materials AG Mike was born in Manchester, 1968. He graduated from the University
More informationIntroduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
More informationInternational Business Management Bachelor of Science in International Business Management
International Business Bachelor of Science in International Business Benefits to the Students The International Business (IBM) Bachelor programme is committed to being international. It is a tri-national
More informationDEPARTMENT OF CHEMISTRY
DEPARTMENT OF CHEMISTRY Brandon University Department of Chemistry Faculty of Science Phone (204) 727-9677 Fax (204) 728-7346 This document is meant as a planning guide only. Students are advised to consult
More informationUK- India Science Bridge: BioPharm 2020
DST INDIA - RESEARCH COUNCILS UK UK- India Science Bridge: BioPharm 2020 Entrepreneurial Opportunities for Indian and UK Scientists in the Pharmaceutical and Biotechnology Industries UK-India Impact Symposium
More informationKazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.
Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology Master s program Bioinformatics I. THEORETICAL BASIS The development of effective technologies of theoretical
More informationEnding cancer. Together.
Ending cancer. Together. Making History by Being First To achieve something as big and bold as ending cancer requires the courage to be first and a willingness to partner with others. At the Robert W.
More informationInfo day in Budapest
European Union European Regional Development Fund From INTERREG IVC to Interreg Europe Info day in Budapest Akos Szabo Project Officer Interreg Europe Secretariat 28 April 2015 Bridge to INTERREG EUROPE
More informationSACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS
SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS Graduate Programs CELL, MOLECULAR, AND DEVELOPMENTAL BIOLOGY CLINICAL
More informationDeutsche Post DHL Group to foster global growth through pioneering innovation approach
Deutsche Post DHL Group to foster global growth through pioneering innovation approach DHL Innovation Center redesigned to speed development of game-changing new services and collaboration with customers
More informationFuture roles and opportunities for statisticians in pharmaceutical industry
Future roles and opportunities for statisticians in pharmaceutical industry H. Ulrich Burger 1), Stefan Driessen 2), Chrissie Fletcher 3), Michael Branson 4), Christoph Gerlinger 5) 1) Hoffmann-La Roche
More informationBachelor of Applied Science in Emergency Medical Services
107 is emerging as one of the UAE s largest growth areas. Student learning takes place in classrooms, laboratories, clinics, and hospital settings where training covers the knowledge, skills, attitudes,
More information2015 Russian Nanotechnology Investment Enabling Technology Leadership Award
2015 Russian Nanotechnology Investment Enabling Technology Leadership Award 2015 Contents Background and Company Performance... 3 Technology Leverage and Customer Impact of OJSC RUSNANO... 3-5 Conclusion...
More informationInvestors' Access. Market. Strategic. Forum. Open. E-Health PROGRAM 2015. Alliance. Innovation PRELIMINARY. Management
OCTOBER 5-6, 2015 PARIS, FRANCE 6 th EDITION THE LEADING PARTNERING MEETING IN OPEN INNOVATION FOR LIFE SCIENCES CONFERENCES EXHIBITION HALL ONE-ON-ONE PARTNERING MEETINGS NETWORKING Open PRELIMINARY PROGRAM
More informationRegulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG
Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory
More informationResearch Awards and Scholarships for Young Female Scientists
Research Awards and Scholarships for Young Female Scientists 1 Research Awards for Women For Women in Science: UNESCO-L'Oréal Support Program for Young Female Basic Scientists in Switzerland Postdocs Biology,
More informationLIVING AND STUDYING IN TOULOUSE
LIVING AND STUDYING IN TOULOUSE With 450 000 inhabitants, Toulouse is the 4th largest city and the 2nd best place to live in France according to a recent poll. Known as the pink city for its ancient brick
More informationU.S. News: Measuring Research Impact
Data Collection Procedures U.S. News: Measuring Research Impact Robert J. Morse, Chief Data Strategist U.S. News & World Report ASEE Engineering Research Council 2016 Annual Conference Sheraton Silver
More informationAnswer Key. Vocabulary Practice
Answer Key Vocabulary Practice Copyright by McDougal Littell, a division of Houghton Mifflin Company A. Categorize Words 1. organism, L; cell, L; species, L; transgenic, B; biotechnology, T; molecular
More information